Group B streptococcus (GBS) is a leading cause of morbidity and mortalityrnamong newborns. Universal screening for GBS among women at 35 to 37 weeks ofrngestation is more effective than administration of intrapartum antibioticsrnbased on risk factors. Lower vaginal and rectal cultures for GBS are collectedrnat 35 to 37 weeks of gestation, and routine clindamycin and erythromycinrnsusceptibility testing is performed in women allergic to penicillin. Women withrnGBS bacteriuria in the current pregnancy and those who previously delivered arnGBS-septic newborn are not screened but automatically receive intrapartumrnantibiotics.